

***Toxic Heavy Metal - Pb, Cd, Sn - Complexation by the
Octadentate Hydroxypyridinonate Ligand Archetype
3,4,3-LI(1,2-HOPO)***

Gauthier J-P. Deblonde¹, Trevor D. Lohrey^{1,2}, Dahlia An¹, Rebecca J. Abergel^{1,3}

¹ *Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA*

² *Department of Chemistry, University of California, Berkeley, CA 94720, USA*

³ *Department of Nuclear Engineering, University of California, Berkeley, CA 94720, USA*

Supporting Information




Figure S 1. Single crystal of $[\text{Sn}^{\text{IV}}3,4,3\text{-LI}(1,2\text{-HOPO})]\cdot 3\text{H}_2\text{O}$.




Figure S 2. **Left:** UV-vis absorbance spectra of samples containing: $40\ \mu\text{M}$ of 3,4,3-LI(1,2-HOPO) and $40\ \mu\text{M}$ of SnCl_4 (pink curve) or $40\ \mu\text{M}$ of 3,4,3-LI(1,2-HOPO) (blue curve). Path length: 10 mm. Background electrolyte: HCl 2 M. Absorbance corrected from blank absorbance (HCl 2 M). $T = 25\ ^\circ\text{C}$. **Right:** Fraction of Sn(IV) released from 3,4,3-LI(1,2-HOPO) as a function of the HCl concentration. The fraction of unbound Sn(IV) was calculated based on the UV-vis absorbance measured at different HCl concentrations.




Figure S 3. Absorbance spectra of a solution containing $40\ \mu\text{M}$ of SnCl_4 and $40\ \mu\text{M}$ of 3,4,3-LI(1,2-HOPO) as a function of pH. 140 spectra measured between pH 1.5 and 11.7. $I = 0.1\ \text{M}$ (KCl), $T = 25\ ^\circ\text{C}$. Path length = 10 mm. **(Left)** Absorbance of the $[\text{Sn}^{\text{IV}}3,4,3\text{-LI}(1,2\text{-HOPO})]^0$ solution at 260 nm (squares), 290 nm (crosses), 320 nm (diamonds), and 360 nm (triangles) as a function of pH. **(B)** Spectra measured between pH 2.0 and 7.1 (70 spectra overlaid).






Figure S4: Top view of the crystal structures of the 3,4,3-Li(1,2-HOPO) complexes with Eu³⁺, Zr⁴⁺, and Sn⁴⁺. The metal ions and the C=O amide bonds are displayed as balls and sticks. The rest of the organic ligand is displayed as capped sticks. The torsion angles between the aromatic 1,2-HOPO units and their C=O amide bonds are 179.6° and 175.2° for Eu³⁺, 84.0° and 109.6° for Zr⁴⁺, and 111.6° for Sn⁴⁺.





Figure S 5. UV-vis spectra of a 50 μM solution of the ligand 3,4,3-LI(1,2-HOPO) (blue curve), a 50 μM solution of Pb(II)-3,4,3-LI(1,2-HOPO) (pink curve), and 50 μM solution of Cd(II)-3,4,3-LI(1,2-HOPO) (green curve). Right: pH = 7.4. Buffer = 0.1 M HEPES. Left: pH = 2 (HCl). The spectra of the free ligand and the sample containing Cd(II) are superimposed at pH 2 showing the lack of metal binding at this pH.

Table S1. Crystallographic details for $[\text{Sn}^{\text{IV}}3,4,3\text{-LI}(1,2\text{-HOPO})]\cdot 3\text{H}_2\text{O}$.

	$[\text{Sn}^{\text{IV}}3,4,3\text{-LI}(1,2\text{-HOPO})]\cdot 3\text{H}_2\text{O}$
Chemical formula	$\text{C}_{34}\text{H}_{40}\text{N}_8\text{O}_{15}\text{Sn}$
Formula weight	919.42
Color, habit	Colorless, shard
Temperature (K)	100(2)
Crystal system	Orthorhombic
Space group	$\text{C}222_1$
a (\AA)	16.0345(7)
b (\AA)	17.0024(7)
c (\AA)	13.3898(6)
α ($^\circ$)	90
β ($^\circ$)	90
γ ($^\circ$)	90
V (\AA^3)	3650.4(3)
Z	4
Density (Mg m^{-3})	1.673
F(000)	1880
Radiation Type	Synchrotron
μ (mm^{-1})	0.938
Crystal size (mm^3)	0.050 x 0.030 x 0.020
Meas. Refl.	31453
Indep. Refl.	8824
R(int)	0.0366
Final R indices [$I > 2\sigma(I)$]	R = 0.0318 R _w = 0.0733
Goodness-of-fit	1.044
Absolute structure parameter	0.001(6)
$\Delta\rho_{\text{max}}, \Delta\rho_{\text{min}}$ (e \AA^{-3})	1.678, -0.910

Negative mode

Pb(II)HOPO 25uM



Negative mode

Cd(II)HOPO 25uM




Figure S 6. High resolution mass spectrometry pattern of 3,4,3-LI(1,2-HOPO) aqueous samples containing 1 equivalent of Pb(II) or Cd(II). [Metal] = [3,4,3(LI-1,2-HOPO)] = 25 μ M. Media: 0.5% formic acid in water. Ionization by electrospray. Negative mode.




Figure S 7. Example of incremental spectrophotometric titration for the Cd(II)-3,4,3-LI(1,2-HOPO) system. 170 spectra measured between pH 1.2 and 11.7. $[Cd] = [3,4,3-LI(1,2-HOPO)] = 55 \mu M$. $I = 0.1 M$ (KCl). Buffer: 5 mM CH₃COOH, 5 mM CHES. $T = 25^\circ C$. Path length = 10 mm. Data abridged for clarity. Spectra corrected from the dilution induced by the addition of the titrant solution.




Figure S 8: Speciation diagram for the ligand 3,4,3-LI(1,2-HOPO) in the presence of 1 equivalent of Pb(II) (left) or 1 equivalent of Cd(II) (right). $T = 25^\circ C$, $I = 0.1 M$ (KCl). $L = 3,4,3-LI(1,2-HOPO)^4$. Hydrolysis constants of the metals were taken into account and set to the values found in the NIST standard reference database 46 at the corresponding ionic strength (Martell, A. E.; Smith, R. M.; Motekaitis, R. J.. National Institute of Standards and Technology: Gaithersburg, MD).




Figure S 9. Calculated distribution of the monomeric species (diamonds) and bimetallic species (circles) for the systems Cd(II)/3,4,3-LI(1,2-HOPO) (left) and Pb(II)/3,4,3-LI(1,2-HOPO) (right) as a function of the molar ratio $[metal]_{total}/[ligand]_{total}$. $pH = 7.4$, $T = 25^\circ C$, $I = 0.1 M$ (KCl).









A. ²¹⁰Pb Kidney Content**B. ²¹⁰Pb Liver Content****C. ²¹⁰Pb Soft Tissue Content****D. ²¹⁰Pb Skeleton Content****E. ²¹⁰Pb Brain Content****F. ²¹⁰Pb Thymus Content****G. ²¹⁰Pb Heart Content****H. ²¹⁰Pb Lungs Content**

Figure S 10. Total ²¹⁰Pb content in kidneys (A), liver (B), soft tissues (C), skeleton (D), brain (E), thymus (F), heart (G), or lungs (H), at 4 days after metal challenge, preceded or followed by a single ip chelation treatment. Young adult female Swiss-Webster mice were injected iv with ²¹⁰Pb-citrate; saline or treatment (3,4,3-LI(1,2-HOPO) or Ca-EDTA [100 μmol/kg] was administered ip at 1 h, 6 h, or 24 h before or at 1 h, 6 h, 24 h, or 48 h after contamination; mice were euthanized 4 days after metal challenge. Data expressed as percent of recovered ²¹⁰Pb dose (% RD, mean ± SD) for each four-mouse group. Groups with significantly different retention than for control mice are indicated by * or ** (p < 0.05 or p < 0.01, 1-way ANOVA with post hoc Dunnett's multiple comparison test).




Figure S 11. Daily ^{210}Pb urinary (A) and fecal (B) output, as well as total ^{210}Pb cumulative excretion relative to control groups (C) at 4 days after a single ip chelation treatment. Young adult female Swiss-Webster mice were injected iv with ^{210}Pb -citrate; saline or treatment (3,4,3-LI(1,2-HOPO) or Ca-EDTA [100 $\mu\text{mol}/\text{kg}$] was administered ip at 1 h, 6 h, or 24 h before or at 1 h, 6 h, 24 h, or 48 h after contamination; mice were euthanized 4 days after metal challenge. Data expressed as percent of recovered ^{210}Pb dose (% RD, mean \pm SD) for each four-mouse group.